Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
Sinan Ma, Jianai Ji, Yuanyuan Tong, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 7, pp. 2990-3005
Open Access | Times Cited: 23

Showing 23 citing articles:

Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Xiaowei Huang, Fengbo Wu, Jing Ye, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2402-2427
Open Access | Times Cited: 14
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Jing Gao, Lei Yang, Shumin Lei, et al.
Science Bulletin (2023) Vol. 68, Iss. 10, pp. 1069-1085
Closed Access | Times Cited: 31
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 25
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics
Lisha Ou, Mekedlawit Setegne, Jeandele Elliot, et al.
Chemical Reviews (2025)
Closed Access
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation
Jianyu Yan, Tengfei Li, Zhenyuan Miao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8798-8827
Closed Access | Times Cited: 28
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
Zhijie Wang, L. Yuan, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6027-6043
Closed Access | Times Cited: 5
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 11
Casitas b cell lymphoma‑B (Cbl-b): A new therapeutic avenue for small-molecule immunotherapy
Xiuqi Hu, Erdong Li, Yangguo Zhou, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 102, pp. 117677-117677
Closed Access | Times Cited: 3
Discovery of novel protein degraders based on bioorthogonal reaction-driven intracellular self-assembly strategy
Ru Si, Huanjie Zhu, Jin Wang, et al.
Bioorganic Chemistry (2023) Vol. 135, pp. 106497-106497
Closed Access | Times Cited: 10
Central Nervous System Targeted Protein Degraders
Bedwyr ab Ion Thomas, H Lewis, D. Heulyn Jones, et al.
Biomolecules (2023) Vol. 13, Iss. 8, pp. 1164-1164
Open Access | Times Cited: 10
Development of DNA Aptamer-Based PROTACs That Degrade the Estrogen Receptor
Haruna Tsujimura, Miyako Naganuma, Nobumichi Ohoka, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 6, pp. 827-832
Open Access | Times Cited: 9
Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
Huifang Wang, Runhua Zhou, Fushan Xu, et al.
Biomaterials Research (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 7
Targeting phosphatases: From molecule design to clinical trials
Mochen Guo, Zekun Li, M. Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 116031-116031
Closed Access | Times Cited: 6
Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis
Xuetao Chen, Tingting Wu, Zhi-Yan Du, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116080-116080
Closed Access | Times Cited: 5
Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8
Tingting Wu, Yali Chen, Qidong You, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116271-116271
Closed Access | Times Cited: 1
Targeting kelch-like (KLHL) proteins: achievements, challenges and perspectives
Yangguo Zhou, Qiong Zhang, Ziquan Zhao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116270-116270
Closed Access | Times Cited: 1
Discovery of a NCOA4 Degrader for Labile Iron-Dependent Ferroptosis Inhibition
Jianai Ji, Yuhui Jin, Sinan Ma, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 12521-12533
Closed Access | Times Cited: 1
How to target membrane proteins for degradation: Bringing GPCRs into the TPD fold
Bogusława Korona, Laura S. Itzhaki
Journal of Biological Chemistry (2024), pp. 107926-107926
Open Access | Times Cited: 1
Incorporating a β-hairpin sequence motif to increase intracellular stability of a peptide-based PROTAC
Hannah C. Hymel, Jeffery C. Anderson, Dong Liu, et al.
Biochemical Engineering Journal (2023) Vol. 199, pp. 109063-109063
Open Access | Times Cited: 4
PROTAC<sup>®</sup> technology and potential for its application in infection control
M. A. Zakharova, М. В. Чудинов
Fine Chemical Technologies (2024) Vol. 19, Iss. 3, pp. 214-231
Open Access
Identification of USP2 as a novel target to induce degradation of KRAS in myeloma cells
Yingying Wang, Youping Zhang, Hao Luo, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 12, pp. 5235-5248
Open Access
Construction of lncRNA- and circRNA-associated ceRNA networks in the prostatic urethra of rats after simulating transurethral laser prostatectomy (TULP)
Xiaohu Tang, ZhiYan Liu, Hao Liu, et al.
Molecular and Cellular Biochemistry (2023) Vol. 479, Iss. 6, pp. 1363-1377
Open Access
Informatically-informed biochemical characterization of aptamer-protein complexes
Paige R. Gruenke
(2022)
Open Access
Page 1

Scroll to top